Thrombosis Journal · 2013 · 16 citations · 40 references
PharmacyPharmacoeconomicsPharmacotherapyCost-effectiveness AnalysisCost-utility AnalysisPharmacoeconomic ModelingAnticoagulant TherapyAnticoagulation TherapyAtrial FibrillationThromboembolism PreventionThrombosisThrombosis PreventionCost-utility Analysis InputsPharmacogenetic-guided DosingPharmacogenetic-guided PrescribingProphylactic AnticoagulationSystemic AnticoagulationTherapeutic AnticoagulationVkorc1 GenotypeVkorc1 Genotyping
BACKGROUND: Atrial fibrillation (AF) is the most common form of heart arrhythmia and a leading cause of stroke and systemic embolism. Chronic anticoagulation is recommended for preventing those complications. Our study aimed to compare the cost/utility (CU) of three main anticoagulation options: 1) standard warfarin dosing (SD-W) 2) warfarin dosage under the guidance of CYP2C9 and VKORC1 genotyping (GT-W) and 3) dabigatran 150 mg twice a day. METHODS: A Markov state transition model was built to simulate the expected C/U of dabigatran, SD-W and GT-W anticoagulation therapy for the prevention of stroke and systemic thromboembolism in patients with atrial fibrillation over a period of 5 years under the perspective of the public health care system. Model inputs were derived from extensive literature search and government's data bases. Outcomes considered were the number of total major events (thromboembolic and hemorrhagic events), total costs in Canadian dollars (1CAD$ = 1$US), total quality-adjusted life years (QALYs), costs/QALYs and incremental costs/QALYs gained (ICUR). RESULTS: Raw base case results show that SD-W has the lowest C/U ratio. However, the dabigatran option might be considered as an alternative, as its cost per additional QALY gained compared to SD-W is CAD $ 4 765, i.e. less than 50 000, the ICUR threshold generally accepted to adopt an intervention. At the same threshold, GT-W doesn't appear to be an alternative to SD-W. Our results were robust to one-way and multi-way sensitivity analyses. CONCLUSION: SD-W has the lowest C/U ratio among the 3 options. However, dabigatran might be considered as an alternative. GT-W is not C/U and should not currently be recommended for the routine anticoagulotherapy management of AF patients.
40
Dabigatran versus Warfarin in Patients with Atrial Fibrillation
Stuart J. Connolly, Michael D. Ezekowitz, Salim Yusuf et al. · New England Journal of Medicine · 2009 · 11.2K citations · Full text
Guidelines on the diagnosis and management of acute pulmonary embolism
Adam Torbicki, Arnaud Perrier, Stavros Konstantinides et al. · European Heart Journal · 2008 · 2.8K citations · Full text
Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism
Sam Schulman, Clive Kearon, Ajay K. Kakkar et al. · New England Journal of Medicine · 2009 · 2.6K citations · Full text